Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of the Use of Hydroxychloroquine, Favipiravir or Hydroxychloroquine + Favipiravir in Early SARS-CoV-2 (COVID-19) Treatment

NCT04981379 is registered in ClinicalTrials.gov with Health Institutes of Turkey as lead sponsor.

NCT NCT04981379
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04981379 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of the Use of Hydroxychloroquine, Favipiravir or Hydroxychloroquine + Favipiravir in Early SARS-CoV-2 (COVID-19) Treatment
Lead sponsor
Health Institutes of Turkey
Phase
Phase 3
Overall status
Completed
Start date
November 16, 2020
Completion date
February 16, 2021
Enrollment
1,120 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

covid19